RT Journal Article
SR Electronic
T1 HostSeq: A Canadian Whole Genome Sequencing and Clinical Data Resource
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.06.22274627
DO 10.1101/2022.05.06.22274627
A1 Yoo, S
A1 Garg, E
A1 Elliott, LT
A1 Hung, RJ
A1 Halevy, AR
A1 Brooks, JD
A1 Bull, SB
A1 Gagnon, F
A1 Greenwood, CMT
A1 Lawless, JF
A1 Paterson, AD
A1 Sun, L
A1 Zawati, MH
A1 Lerner-Ellis, J
A1 Abraham, RJS
A1 Birol, I
A1 Bourque, G
A1 Garant, J-M
A1 Gosselin, C
A1 Li, J
A1 Whitney, J
A1 Thiruvahindrapuram, B
A1 Herbrick, J-A
A1 Lorenti, M
A1 Reuter, MS
A1 Liu, S
A1 Allen, U
A1 Bernier, FP
A1 Biggs, CM
A1 Cheung, AM
A1 Cowan, J
A1 Herridge, M
A1 Maslove, DM
A1 Modi, BP
A1 Mooser, V
A1 Morris, SK
A1 Ostrowski, M
A1 Parekh, RS
A1 Pfeffer, G
A1 Suchowersky, O
A1 Taher, J
A1 Turvey, SE
A1 Upton, J
A1 Warren, RL
A1 Yeung, RSM
A1 Aziz, N
A1 Knoppers, BM
A1 Lathrop, M
A1 Jones, SJM
A1 Scherer, SW
A1 Strug, LJ
YR 2022
UL http://medrxiv.org/content/early/2022/05/10/2022.05.06.22274627.abstract
AB HostSeq was launched in April 2020 as a national initiative to integrate whole genome sequencing data from 10,000 Canadians infected with SARS-CoV-2 with clinical information related to their disease experience. The mandate of HostSeq is to support the Canadian and international research communities in their efforts to understand the risk factors for disease and associated health outcomes and support the development of interventions such as vaccines and therapeutics. HostSeq is a collaboration among 13 independent epidemiological studies of SARS-CoV-2 across five provinces in Canada. Aggregated data collected by HostSeq are made available to the public through two data portals: a phenotype portal showing summaries of major variables and their distributions, and a variant search portal enabling queries in a genomic region. Individual-level data is available to the global research community through a Data Access Agreement and Data Access Compliance Office approval. Here we provide an overview of the collective project design along with summary level information for HostSeq. We highlight several statistical considerations for researchers using the HostSeq platform regarding data aggregation, sampling mechanism, covariate adjustment, and X chromosome analysis. In addition to serving as a rich data source, the diversity of study designs, sample sizes, and research objectives among the participating studies provides unique opportunities for the research community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are very thankful for the support we received from Genome Canada, Innovation, Science and Economic Development Canada, SickKids Foundation, Toronto Academic Health Science Network (TAHSN), CFI, CIHR, COVID-19 Immunity Task Force (CITF), Ministry of Colleges and Universities COVID-19 Rapid Research Fund, Michael Smith Health Research BC, PHCRI Early Career Award, Genome Alberta and the Alberta Children's Hospital Foundation, and internal support from the Hotchkiss Brain Institute and Department of Clinical Neurosciences (University of Calgary).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board of The Hospital for Sick Children, Toronto, Ontario, Canada gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available through a Data Access Agreement and Data Access Compliance Office approval. http://www.cgen.ca/daco-main https://www.cgen.ca/hostseq-studies-2 https://hostseq.ca/phenotypes.html https://hostseq.ca/dashboard/variants-search